1. Home
  2. CASI vs WIMI Comparison

CASI vs WIMI Comparison

Compare CASI & WIMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • WIMI
  • Stock Information
  • Founded
  • CASI 1991
  • WIMI 2015
  • Country
  • CASI China
  • WIMI China
  • Employees
  • CASI N/A
  • WIMI N/A
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • WIMI Computer Software: Prepackaged Software
  • Sector
  • CASI Health Care
  • WIMI Technology
  • Exchange
  • CASI Nasdaq
  • WIMI Nasdaq
  • Market Cap
  • CASI 35.8M
  • WIMI 38.3M
  • IPO Year
  • CASI 1996
  • WIMI 2020
  • Fundamental
  • Price
  • CASI $1.84
  • WIMI $4.67
  • Analyst Decision
  • CASI Strong Buy
  • WIMI
  • Analyst Count
  • CASI 1
  • WIMI 0
  • Target Price
  • CASI $4.00
  • WIMI N/A
  • AVG Volume (30 Days)
  • CASI 305.0K
  • WIMI 508.0K
  • Earning Date
  • CASI 11-13-2025
  • WIMI 01-01-0001
  • Dividend Yield
  • CASI N/A
  • WIMI N/A
  • EPS Growth
  • CASI N/A
  • WIMI N/A
  • EPS
  • CASI N/A
  • WIMI 1.43
  • Revenue
  • CASI $31,564,000.00
  • WIMI $61,329,146.00
  • Revenue This Year
  • CASI N/A
  • WIMI N/A
  • Revenue Next Year
  • CASI N/A
  • WIMI N/A
  • P/E Ratio
  • CASI N/A
  • WIMI $3.43
  • Revenue Growth
  • CASI 36.64
  • WIMI N/A
  • 52 Week Low
  • CASI $1.09
  • WIMI $2.24
  • 52 Week High
  • CASI $7.50
  • WIMI $29.20
  • Technical
  • Relative Strength Index (RSI)
  • CASI 51.04
  • WIMI 56.96
  • Support Level
  • CASI $1.77
  • WIMI $4.61
  • Resistance Level
  • CASI $2.08
  • WIMI $5.04
  • Average True Range (ATR)
  • CASI 0.20
  • WIMI 0.47
  • MACD
  • CASI 0.02
  • WIMI -0.02
  • Stochastic Oscillator
  • CASI 71.84
  • WIMI 28.36

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

Share on Social Networks: